Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
– 2023 marked by Ceapro’s achievement of key milestones and progress toward its next phase of growth
– R&D activities focused on advancement of avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology
Related news for (CRPOF)
- Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
- Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
- Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
- Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company